<DOC>
	<DOCNO>NCT01108458</DOCNO>
	<brief_summary>A phase 2 study combine pertuzumab erlotinib patient gemcitabine refractory pancreatic adenocarcinoma</brief_summary>
	<brief_title>A Phase 2 Study Pertuzumab Erlotinib Refractory Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>A single-institution , single-arm phase 2 study investigate pertuzumab erlotinib palliative regimen treatment locally-advanced metastatic pancreatic adenocarcinoma .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>3.1 Inclusion Criteria 3.1.1 Histologicallyconfirmed pancreatic adenocarcinoma 3.1.2 One locallyadvanced metastatic lesion measurable least one dimension modify RECIST criterion ( v1.1 ) ^13 within 4 week prior entry study 3.1.3 Prior therapy ( 1 ) : 3.1.3.1 Disease progression follow therapy gemcitabine 3.1.3.2 Intolerance gemcitabine 3.1.3.3 Disease recurrence within 12 month follow adjuvant gemcitabine 3.1.4 Age &gt; = 18 3.1.5 ECOG performance status 02 3.1.6 Laboratory value &lt; = 2 week prior enrollment : Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L ( &gt; = 1500/mm^3 ) Platelets ( Plt ) &gt; = 100,000/mm^3 Hemoglobin ( Hgb ) &gt; = 9 g/dL Serum creatinine &lt; = 1.5 x ULN Serum bilirubin &lt; = 1.5 x ULN ( &lt; = 3.0 x ULN liver metastasis present ) Aspartate aminotransferase ( AST/SGOT ) , alanine aminotransferase ( ALT/SGPT ) &lt; = 3.0 x ULN . ( &lt; = 5.0 x ULN liver metastasis present ) . ERCP percutaneous stenting may use normalize liver function test 3.1.7 Echocardiogram MUGA scan demonstrate LVEF &gt; = 50 % within 4 week trial entry 3.1.8 Ability understand willingness sign write informed consent document . 3.2 DiseaseSpecific Exclusion Criteria 3.2.1 Prior therapy EGFRtargeted agent 3.2.2 If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present treatment administer last 3 year 3.3 General Medical Exclusion Criteria 3.3.1 Subjects know chronic active hepatitis B C infection impair hepatic function ( ineligible AST ALT &gt; 3.0 x ULN ) . 3.3.2 History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation study drug administration may interfere conduct study interpretation study result 3.3.3 Male subject willing use adequate contraception upon enrollment study 6 month follow last dose study agent 3.3.4 Female subject ( childbearing potential , postmenopausal le 6 month , surgically sterilize , abstinent ) willing use oral , patch implant contraceptive , doublebarrier birth control , IUD course study 6 month follow last dose secondline treatment 3.3.5 Female subject breastfeed positive serum pregnancy test 72 hour prior enrollment 3.3.6 Any follow concurrent severe and/or uncontrolled medical condition within 24 week enrollment could compromise participation study : Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction &lt; = 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Chronic renal disease 3.3.7 Patients unwilling unable comply protocol 3.3.8 Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentech/Roche sponsor cancer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>